PBE
PowerShares Dynamic Biotechnology & Genome Portfolio

Up$55.53
+$2.20
(+4.13%)
As of 12:00:00 AM EDT | 10/16/18  |  Market Closed

PBE Trading Data

Open

$53.74

Low Price

$53.68

High Price

$55.55

Previous Last Price

$53.33

Bid Size

$0 X 0

Ask Size

$0 X 0

PBE Portfolio Data

AUM

$277,264,000

Shares

5,200

PE Ratio

74.23

Price / Book Ratio

4.47

Expense Ratio

0.58

Net Asset Value

$53.32

Volume

Volume

22,300

Avg. Volume (YDT)

21,180

Dollar Volume

$1,141,359

Weekly Avg. Volume

99,440

Monthly Avg. Volume

38,360

Quarterly Avg. Volume

33,875

PBE Fund Description

The PowerShares Dynamic Biotechnology and Genome Portfolio is based on the Dynamic Biotech and Genome Intellidex Index. The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Intellidex Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The Underlying Intellidex Index is comprised of common stocks of 30 US biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November.

PBE Chart

PBE Summary

Fund Family

Invesco PowerShares

Tracks This Index

PowerShares Dynamic Biotechnology & Genome Portfolio

Inception Date

2005-06-23

Asset Class

Equity

Asset Class Size

Biotech

PBE Classification

Region (General)

North America

Region (Specific)

US

Sector

Health Care

Equity Index

Leveraged Family

PBE Holdings

Top 10 Holdings

Amgen Inc (AMGN)
5.51%
Vertex Pharmaceuticals Inc (VRTX)
5.39%
Biogen Inc (BIIB)
5.26%
Regeneron Pharmaceuticals Inc (REGN)
5.22%
Neurocrine Biosciences Inc (NBIX)
5.09%
Illumina Inc (ILMN)
5.01%
QIAGEN NV (QGEN)
4.96%
Nektar Therapeutics (NKTR)
4.2%
Genomic Health Inc (GHDX)
3.25%
Catalent Inc (CTLT)
3.08%

Total PBE Holdings

Total Holdings: 31

Amgen Inc (AMGN)
5.51%
Vertex Pharmaceuticals Inc (VRTX)
5.39%
Biogen Inc (BIIB)
5.26%
Regeneron Pharmaceuticals Inc (REGN)
5.22%
Neurocrine Biosciences Inc (NBIX)
5.09%
Illumina Inc (ILMN)
5.01%
QIAGEN NV (QGEN)
4.96%
Nektar Therapeutics (NKTR)
4.2%
Genomic Health Inc (GHDX)
3.25%
Catalent Inc (CTLT)
3.08%
United Therapeutics Corp (UTHR)
3.07%
Repligen Corp (RGEN)
3.05%
Ionis Pharmaceuticals Inc (IONS)
2.99%
Emergent BioSolutions Inc (EBS)
2.96%
Loxo Oncology Inc (LOXO)
2.94%
Bio-Techne Corp (TECH)
2.93%
Halozyme Therapeutics Inc (HALO)
2.9%
Cardiovascular Systems Inc (CSII)
2.88%
PTC Therapeutics Inc (PTCT)
2.8%
Alkermes PLC (ALKS)
2.79%
WaVe Life Sciences Ltd (WVE)
2.72%
Myriad Genetics Inc (MYGN)
2.71%
Ironwood Pharmaceuticals Inc (IRWD)
2.61%
Enanta Pharmaceuticals Inc (ENTA)
2.6%
Exelixis Inc (EXEL)
2.54%
REGENXBIO Inc (RGNX)
2.48%
Sangamo Therapeutics Inc (SGMO)
2.36%
Acorda Therapeutics Inc (ACOR)
1.97%
OPKO Health Inc (OPK)
1.92%
Momenta Pharmaceuticals Inc (MNTA)
1.8%
PowerShares Dynamic Biotechnology & Genome Portfolio (PBE)
0%

PBE Technicals

Alpha

-11.52

Beta

1.36

Leverage

Long

Standard Deviation

4.72

PBE Dividends

Dividend Date

2018-09-24

Latest Dividend

0.002

Annual Dividend

0

Annual Dividend Rate

0

Annual Dividend Yield

1.0E-5

PBE Performance

YTD Return

17.75%

1 Year Return

12.41%

3 Year Return

14.59%

5 Year Return

54.81%

10 Year Return

279.3%

PBE Related Articles

Biotech ETFs Rally as Illumina Tops Q2 Expectations

Biotech ETFs Rally as Illumina Tops Q2 Expectations

Biotechnology sector ETFs were among the best performers Tuesday, with Illumina (NasdaqGS: ILMN) shares surging after the genomics firm beat second-quarter expectations and raised its year-end outlook. Among the best…

Healthcare ETFs Are Latest Victim to Trump

Healthcare ETFs Are Latest Victim to Trump

Healthcare stocks, especially the biotech segment, and related exchange traded funds plunged Wednesday after President-elect Donald Trump singled out the rising drug prices at a press conference. The healthcare sector…

Pfizer Acquires Medivation, Renews Biotech M&A Bets

Pfizer Acquires Medivation, Renews Biotech M&A Bets

Pfizer (NYSE: PFE) announced a $14 billion deal to acquire cancer drug developer Medivation (NasdaqGS: MDVN), propelling the broader biotechnology exchange traded funds higher on speculation of more deals in…

Hit The Lab With These 17 Biotech ETFs

Hit The Lab With These 17 Biotech ETFs

The time to buy, regardless of sector, is usually when a particular group falls out of favor, not when it has been bid higher by scores of investors. Some investors…